查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1926850

BRAF抑制剂市场按适应症、药物类型、治疗领域、通路和最终用户划分－2026-2032年全球预测

BRAF Inhibitors Market by Indication, Drug Type, Therapy Line, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计 BRAF 抑制剂市场在 2025 年的价值为 15.5 亿美元，在 2026 年成长至 16.6 亿美元，复合年增长率为 7.94%，到 2032 年将达到 26.5 亿美元。

关键市场统计数据
基准年 2025 15.5亿美元
预计年份：2026年 16.6亿美元
预测年份 2032 26.5亿美元
复合年增长率 (%) 7.94%

本文全面介绍了分子诊断、治疗顺序和门诊护理方面的趋势如何重塑BRAF抑制剂在肿瘤学中的应用。

BRAF突变驱动型恶性肿瘤的治疗格局正从以单一疗法为中心的模式转向需要精细临床和商业性规划的综合性、多方面策略。分子诊断技术的进步使得BRAF V600突变的检测在许多肿瘤治疗路径中成为常规操作。这种分子层面的可及性推动了对标靶小分子抑制剂及伴随诊断的需求。因此，临床开发、医院处方集和专科诊所的相关人员正在重新审视治疗流程，以优化治疗顺序、联合治疗和患者选择标准。

对正在从根本上改变BRAF抑制剂治疗模式和市场动态的临床、诊断和商业性转折点进行详细说明。

近年来，在更深入的分子分层和不断发展的联合治疗方法方案的推动下，临床医生、监管机构和商业团队对BRAF抑制剂的态度发生了变革性转变。临床实务越来越重视联合标靶策略，以延缓或克服MAPK通路抗药性，这促使处方医师探索联合治疗，并将次世代定序整合到常规诊断流程中。这一趋势也影响临床试验设计，使其转向以生物标记为特征的队列和适应性通讯协定，旨在加速BRAF抑制剂在多种肿瘤类型中的适应症扩展。

对2025年关税主导的贸易动态如何重塑BRAF抑制剂生态系统的供应链、筹资策略和商业协议进行全面评估

2025年关税的实施和贸易政策调整正对BRAF抑制剂供应链的筹资策略、製造地地点和供应链韧性施加累积压力。从国际原料药的製造商面临更高的到岸成本，因此正在加速供应商多元化、将关键流程迁回国内或加强垂直整合以降低风险。这些应对措施正在影响医院和零售药局（这些药局负责肿瘤药物处方集）的合约週期、库存管理和前置作业时间。

详细的細項分析清楚地展示了适应症、药物类型、分销管道、最终用户、治疗方案和口服给药途径等因素如何相互交织，从而驱动策略选择。

细分市场分析揭示了在考虑适应症、药物类型、分销管道、终端用户、治疗方案和给药途径等因素时，临床和商业性动态存在差异。例如，在大肠直肠癌（早期大肠直肠癌和转移性大肠直肠癌）、肺癌（非小细胞肺癌和小细胞肺癌亚型）以及黑色素瘤（进行性和转移性）等适应症类别中，临床路径的复杂程度差异显着。转移性大肠直肠癌的治疗重点在于系统性治疗的顺序和合併治疗策略，而早期大肠直肠癌的治疗则更着重于根治性治疗和辅助性治疗的决策。

策略区域观点：深入分析美洲、欧洲、中东和非洲以及亚太地区法规结构、支付方趋势和诊断能力的差异，以及这些差异如何影响医疗服务的可及性和普及率。

区域趋势对美洲、欧洲、中东和非洲以及亚太地区的监管路径、临床应用和商业性准入有显着影响。在美洲，某些司法管辖区的监管协调以及支付方的强大影响力促使相关人员优先考虑产生可靠的真实世界证据和卫生经济学模型，以支持药物上市。该地区的临床试验网络和学术机构通常率先采用者标籤扩展研究，从而加速了BRAF标靶治疗的诊断应用和处方医生采纳。

在BRAF疗法领域，决定永续商业性优势的策略考量包括：投资组合策略、诊断合作、供应链选择以及伙伴关係发展。

BRAF抑制剂研发和商业化领域的公司之间的竞争取决于产品组合的广度、诊断伙伴关係以及供应链整合。拥有多元化肿瘤产品组合的公司可以利用跨产品组合的协同效应来支持市场进入，而专科公司则倾向于专注于扩展适应症、开展联合用药研究以及与关键高管进行有针对性的沟通，以推动药物在特定适应症领域的应用。治疗药物研发公司与诊断服务提供者之间的伙伴关係是成功商业化的基石，它能够确保及时检测到突变，并使报销文件与临床决策通讯协定保持一致。

为製造商、支付方和医疗服务提供者提供以行动为导向的策略建议，以协调诊断、供应链弹性和商业性执行，从而实现持续的市场成功。

为了最大限度地发挥BRAF标靶治疗的价值，产业领导者应优先考虑整合临床开发和诊断、供应链韧性以及客製化商业性准入途径的策略。投资于永续的诊断伙伴关係和就地检验途径将加速识别合适的患者，并加强与支付方的沟通。同时，应设计真实世界证据项目，以解决对临床医生和医保机构至关重要的疗效比较和长期安全性问题。在营运方面，企业应进行供应链压力测试，以应对关税和贸易衝击；考虑关键原料药（API）的双重采购；并在成本效益允许的情况下评估近岸外包和垂直整合，以保障供应的连续性。

应清楚解释混合调查方法，该方法结合了专家访谈、监管检验和文献检验，以确保研究结果的可靠性和可操作性。

本分析的调查方法结合了对肿瘤临床医生、药房主任和市场进入专家的定性调查，以及系统性的二手文献回顾和公开的监管记录。研究人员还采访了关键产业领袖（KOL），检验临床应用模式、实际治疗顺序以及对诊断工作流程的实际影响。此外，与医院采购人员、专科药房营运商和独立诊所经理的讨论揭示了合约结构和库存管理实践方面的差异，并深入分析了供应链和分销管道。

一份简洁、全面且全面的分析报告，强调了整合临床证据、诊断完整性和供应链韧性对于提升病患就医便利性和商业性绩效的重要性。

一项综合分析表明，BRAF抑制剂领域的成功需要临床差异化、诊断完整性和操作韧性的全面整合。临床进展和合併治疗策略需要同步产生证据，并制定切实可行的商业化计划，以反映门诊口服治疗的实际情况。供应链和贸易政策趋势，包括关税带来的成本压力，凸显了来源多元化和积极筹资策略的重要性，以维持医疗服务环境中的连续性并控製成本。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. BRAF抑制剂市场依适应症划分

  • 大肠直肠癌
    • 早期大肠直肠癌
    • MCRC
  • 肺癌
    • NSCLC
    • SCLC
  • 黑色素瘤
    • 进行性黑色素瘤
    • 转移性黑色素瘤

9. BRAF抑制剂市场依药物类型划分

  • Dabrafenib
  • Encorafenib
  • Vemurafenib

10. BRAF抑制剂市场依治疗领域划分

  • 一线治疗
  • 二级治疗

第十一章：BRAF抑制剂市场（依分销管道划分）

  • 医院药房
    • 私立医院药房
    • 公立医院药房
  • 网路药房
  • 零售药房
    • 连锁药局
    • 独立药房

第十二章：BRAF抑制剂市场（依最终用户划分）

  • 医院
    • 综合医院
    • 专科癌症中心
  • 专科诊所
    • 医院门诊部
    • 独立诊所

13. BRAF抑制剂市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：BRAF抑制剂市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：各国BRAF抑制剂市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国BRAF抑制剂市场

17. 中国BRAF抑制剂市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Asana BioSciences LLC
  • AstraZeneca
  • Bayer AG
  • BeiGene Ltd.
  • Black Diamond Therapeutics Inc
  • Bristol-Myers Squibb
  • C4 Therapeutics
  • F. Hoffmann-La Roche Ltd.
  • Fore Biotherapeutics Inc
  • Jazz Pharmaceuticals Plc
  • Kinnate Biopharma Inc.
  • Nerviano Medical Sciences Srl
  • Novartis International AG
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.
Product Code: MRR-4F7A6D4FF333

The BRAF Inhibitors Market was valued at USD 1.55 billion in 2025 and is projected to grow to USD 1.66 billion in 2026, with a CAGR of 7.94%, reaching USD 2.65 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.55 billion
Estimated Year [2026] USD 1.66 billion
Forecast Year [2032] USD 2.65 billion
CAGR (%) 7.94%

Comprehensive context on how molecular diagnostics, treatment sequencing, and outpatient care trends are reshaping BRAF inhibitor use across oncology settings

The treatment landscape for BRAF-driven malignancies has moved from monotherapy-centric approaches toward integrated, multidisciplinary strategies that require nuanced clinical and commercial planning. Advances in molecular diagnostics have made identification of BRAF V600 mutations routine in many oncology care pathways, and this molecular visibility has driven demand for targeted small-molecule inhibitors alongside companion diagnostics. As a result, stakeholders across clinical development, hospital formularies, and specialty clinics are reassessing treatment algorithms to optimize sequencing, combination regimens, and patient selection criteria.

This introductory overview frames the strategic implications for manufacturers, payers, and provider systems by highlighting the interplay between emerging clinical evidence, diagnostic adoption, and distribution dynamics. It underscores the importance of aligning supply chain capabilities and commercial channels with evolving prescriber preferences and outpatient care models. By setting this context, readers can better interpret subsequent sections that examine therapeutic shifts, tariff-driven supply impacts, segmentation-specific nuances, and regional differentials that shape access and uptake of oral BRAF inhibitors in contemporary oncology practice.

Detailed explanation of the clinical, diagnostic, and commercial inflection points that are fundamentally altering BRAF inhibitor treatment paradigms and market behavior

Recent years have delivered transformative shifts in how clinicians, regulators, and commercial teams approach BRAF inhibition, driven by deeper molecular stratification and evolving therapeutic combinations. Clinical practice has increasingly favored co-targeting strategies to delay or overcome MAPK pathway resistance, prompting prescribers to consider combination regimens and to integrate next-generation sequencing into routine diagnostic workflows. This trend has also influenced trial design toward biomarker-enriched cohorts and adaptive protocols that seek to accelerate label expansions across multiple tumor types.

Concurrently, the commercial landscape is adapting to the emergence of oral-only administration paradigms and decentralized care delivery, which places greater emphasis on outpatient support programs, adherence monitoring, and digital patient engagement. Distribution channels are shifting as hospital pharmacies negotiate tighter formulary criteria while online and retail pharmacies expand services to support oral oncology agents. These changes are accompanied by intensified collaboration between drug developers and diagnostic providers to ensure timely mutation detection and appropriate patient selection, thereby closing the loop between laboratory insights and therapeutic decision-making.

Comprehensive assessment of how tariff-driven trade shifts in 2025 are reshaping supply chains, procurement strategies, and commercial contracting across the BRAF inhibitor ecosystem

The imposition of tariffs and trade policy adjustments in 2025 exert cumulative pressure on procurement strategies, manufacturing footprints, and supply chain resilience for BRAF inhibitor supply chains. Manufacturers sourcing active pharmaceutical ingredients internationally have faced higher landed costs and have accelerated supplier diversification, reshoring of critical steps, or greater vertical integration to mitigate exposure. These operational responses have consequences across contracting cycles, inventory management, and lead times for hospital and retail pharmacies that maintain oncology formularies.

From a commercial perspective, payers and provider systems are reassessing cost-containment levers and reimbursement pathways as procurement economics shift. Larger integrated manufacturers with global supply networks are better positioned to absorb short-term tariff-related cost increases, while smaller specialty firms and contract manufacturers may seek to renegotiate distribution agreements or prioritize markets with more favorable trade terms. In parallel, distribution channel strategies have evolved with hospital pharmacies and specialty clinics emphasizing longer-term procurement planning and online and retail pharmacies leveraging centralized logistics to smooth episodic supply disruptions. Overall, tariffs have catalyzed longer-term supply chain optimization, with implications for pricing negotiations, procurement flexibility, and strategic partnership formation across the ecosystem.

In-depth segmentation intelligence articulating how indication, drug type, distribution channel, end-user, therapy line, and oral administration intersect to drive strategic choices

Segmentation analysis reveals distinct clinical and commercial dynamics when examining indications, drug types, distribution channels, end users, therapy lines, and routes of administration in an integrated manner. When considering indication breakdowns across colorectal cancer with both early-stage CRC and metastatic CRC, lung cancer characterized by NSCLC and SCLC subtypes, and melanoma with advanced and metastatic presentations, clinical pathway complexity varies substantially: metastatic settings emphasize systemic sequencing and combination strategies while early-stage contexts prioritize curative-intent considerations and adjuvant decision-making.

Drug-specific differentiation among dabrafenib, encorafenib, and vemurafenib manifests in clinical positioning, dosing schedules, and historical evidence bases; these characteristics inform lifecycle management and real-world utilization patterns. Distribution channel nuance between hospital pharmacy environments that include private and public facilities, online pharmacy capabilities, and retail pharmacy formats comprised of chain and independent operators affects patient access pathways and reimbursement interactions. End-user segmentation contrasts hospitals, which include general hospitals and specialty cancer centers, with specialist clinics that span hospital outpatient clinics and independent clinics, and this split influences prescribing concentration, clinical trial participation, and supportive care infrastructure. Therapy line segmentation into first-line and second-line use cases dictates enrollment strategies, payer negotiations, and diagnostic adoption, whereas the oral route of administration simplifies outpatient delivery but increases the importance of adherence programs and remote monitoring solutions. Together, these segmentation lenses provide a multidimensional framework to align clinical trial design, market access planning, and commercial operations with where and how patients actually receive BRAF-directed therapies.

Strategic regional perspective detailing how regulatory frameworks, payer dynamics, and diagnostic capacity vary across the Americas, Europe Middle East and Africa, and Asia-Pacific influencing access and adoption

Regional dynamics exert pronounced influence on regulatory pathways, clinical adoption, and commercial access across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, regulatory harmonization in certain jurisdictions and strong payer influence lead stakeholders to emphasize robust real-world evidence generation and health economics modeling to support formulary placement. Clinical trial networks and academic centers in this region often act as early adopters for label-expanding studies, which in turn accelerates diagnostic uptake and prescriber familiarity with BRAF-targeted regimens.

Europe, the Middle East & Africa present a heterogeneous mosaic where centralized regulatory processes coexist with diverse reimbursement frameworks, prompting manufacturers to develop differentiated access strategies that include managed entry agreements and region-specific evidence packages. In parts of this region, constrained healthcare budgets and variable diagnostic capacity require targeted investments in laboratory infrastructure and provider education. Asia-Pacific is characterized by rapid capacity building in molecular diagnostics, expanding clinical research activity, and strategic manufacturing hubs, which can benefit both supply security and localized clinical data generation. Taken together, these regional profiles inform prioritization of regulatory filings, commercialization sequencing, and partnerships that optimize patient access while respecting local payer and provider nuances.

Corporate strategic read on how portfolio strategies, diagnostic collaborations, supply chain choices, and partnership architectures determine durable commercial advantage in BRAF therapies

Competitive dynamics among companies engaged in BRAF inhibitor development and commercialization are defined by portfolio breadth, diagnostic partnerships, and supply chain integration. Organizations with diversified oncology portfolios can leverage cross-portfolio synergies to support market access, while specialty firms often focus on label expansion, combination studies, and targeted engagement with key opinion leaders to drive adoption in niche indications. Partnerships between therapeutic developers and diagnostic providers have become a cornerstone of successful commercialization, ensuring timely mutation detection and aligning reimbursement dossiers with clinical decision-making protocols.

Strategic maneuvers such as licensing deals, co-development agreements, and selective acquisitions of complementary assets have become common as companies seek to enhance evidence generation and secure market positions. Manufacturing strategy, including the use of contract development and manufacturing organizations versus in-house API production, influences cost structures and supply resilience. Companies that prioritize patient support, adherence programs, and digital health initiatives improve long-term treatment retention and commercial outcomes. Collectively, these company-level insights highlight the importance of an integrated approach that couples clinical differentiation with pragmatic operational execution to sustain competitive advantage.

Action-oriented strategic recommendations for manufacturers, payers, and providers to align diagnostics, supply resilience, and commercial execution for sustained market success

Industry leaders should prioritize an integrated strategy that aligns clinical development with diagnostics, supply chain resilience, and tailored commercial access pathways to maximize the value of BRAF-targeted assets. Investment in durable diagnostic partnerships and point-of-care testing pathways will accelerate appropriate patient identification and strengthen payer conversations, while concurrent real-world evidence programs should be designed to address comparative effectiveness and long-term safety questions that matter to clinicians and reimbursement bodies. Operationally, firms must stress test supply chains for tariff and trade shocks, consider dual-sourcing for critical APIs, and evaluate nearshoring or vertical integration where cost-effective to protect continuity of supply.

Commercial teams should expand patient support and adherence programs to reflect the oral route of administration and to enable decentralized care models that reduce barriers to therapy initiation and continuation. Engagement with hospital formulary committees, specialty clinics, and retail pharmacy networks must be tailored by segment to reflect prescribing concentration and procurement dynamics. Finally, cross-functional alignment between clinical, regulatory, government affairs, and commercial teams will accelerate market access wins and facilitate agile responses to policy changes, reimbursement shifts, and emerging clinical evidence.

Transparent description of the mixed methods research approach combining expert interviews, regulatory validation, and literature triangulation to ensure credible and actionable insights

The research methodology underpinning this analysis combined primary qualitative engagement with oncology clinicians, pharmacy directors, and market access specialists alongside systematic secondary literature review and public regulatory records. Key opinion leader interviews were conducted to validate clinical adoption patterns, real-world treatment sequencing, and the practical implications of diagnostic workflows. Supply chain and distribution channel insights were obtained through discussions with hospital procurement leaders, specialty pharmacy operators, and independent clinic administrators to capture differences in contracting and inventory practices.

Findings were triangulated across sources and cross-validated against regulatory approvals, clinical trial registries, and published peer-reviewed evidence to ensure accuracy and relevance. Where discrepancies emerged, follow-up interviews and document-level verification were used to reconcile interpretations. The methodology emphasizes transparency in assumptions, clear articulation of data provenance, and acknowledgment of limitations such as variable regional reporting practices and evolving clinical trial outcomes that may change the evidence base over time. This approach yields a defensible and actionable evidence set suitable for strategic planning and commercial decision-making.

Concise synthesis highlighting the imperative to integrate clinical evidence, diagnostic alignment, and supply chain resilience to drive patient access and commercial performance

The cumulative analysis underscores that success in the BRAF inhibitor space is contingent upon a holistic integration of clinical differentiation, diagnostic alignment, and operational resilience. Clinical advancements and combination strategies require synchronized evidence generation and pragmatic commercialization plans that reflect the realities of outpatient oral therapy delivery. Supply chain and trade policy dynamics, including tariff-driven cost pressures, have heightened the importance of diversified sourcing and proactive procurement strategies to maintain continuity and control costs in provider settings.

Regional heterogeneity in regulatory and reimbursement environments necessitates tailored market entry and access approaches, while segmentation insights reveal where investment in diagnostics, patient support, and provider education will yield the greatest return in terms of uptake and persistence. Collectively, these conclusions point to a strategic imperative for manufacturers and partners to adopt adaptive, evidence-driven approaches that bridge clinical innovation with real-world delivery, ensuring patients can access appropriate BRAF-targeted therapies across diverse care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. BRAF Inhibitors Market, by Indication

  • 8.1. Colorectal Cancer
    • 8.1.1. Early Stage Crc
    • 8.1.2. Mcrc
  • 8.2. Lung Cancer
    • 8.2.1. Nsclc
    • 8.2.2. Sclc
  • 8.3. Melanoma
    • 8.3.1. Advanced Melanoma
    • 8.3.2. Metastatic Melanoma

9. BRAF Inhibitors Market, by Drug Type

  • 9.1. Dabrafenib
  • 9.2. Encorafenib
  • 9.3. Vemurafenib

10. BRAF Inhibitors Market, by Therapy Line

  • 10.1. First Line
  • 10.2. Second Line

11. BRAF Inhibitors Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
    • 11.1.1. Private Hospital Pharmacy
    • 11.1.2. Public Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy
    • 11.3.1. Chain Pharmacy
    • 11.3.2. Independent Pharmacy

12. BRAF Inhibitors Market, by End User

  • 12.1. Hospitals
    • 12.1.1. General Hospitals
    • 12.1.2. Specialty Cancer Centers
  • 12.2. Specialist Clinics
    • 12.2.1. Hospital Outpatient Clinics
    • 12.2.2. Independent Clinics

13. BRAF Inhibitors Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. BRAF Inhibitors Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. BRAF Inhibitors Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States BRAF Inhibitors Market

17. China BRAF Inhibitors Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Asana BioSciences LLC
  • 18.6. AstraZeneca
  • 18.7. Bayer AG
  • 18.8. BeiGene Ltd.
  • 18.9. Black Diamond Therapeutics Inc
  • 18.10. Bristol-Myers Squibb
  • 18.11. C4 Therapeutics
  • 18.12. F. Hoffmann-La Roche Ltd.
  • 18.13. Fore Biotherapeutics Inc
  • 18.14. Jazz Pharmaceuticals Plc
  • 18.15. Kinnate Biopharma Inc.
  • 18.16. Nerviano Medical Sciences S.r.l
  • 18.17. Novartis International AG
  • 18.18. Ono Pharmaceutical Co. Ltd.
  • 18.19. Pfizer Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAF INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAF INHIBITORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRAF INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAF INHIBITORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRAF INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAF INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BRAF INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BRAF INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRAF INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAF INHIBITORS MARKET SIZE, BY EARLY STAGE CRC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRAF INHIBITORS MARKET SIZE, BY EARLY STAGE CRC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAF INHIBITORS MARKET SIZE, BY EARLY STAGE CRC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRAF INHIBITORS MARKET SIZE, BY MCRC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAF INHIBITORS MARKET SIZE, BY MCRC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRAF INHIBITORS MARKET SIZE, BY MCRC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAF INHIBITORS MARKET SIZE, BY NSCLC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRAF INHIBITORS MARKET SIZE, BY NSCLC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAF INHIBITORS MARKET SIZE, BY NSCLC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SCLC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SCLC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SCLC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAF INHIBITORS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRAF INHIBITORS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAF INHIBITORS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ADVANCED MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ADVANCED MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ADVANCED MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRAF INHIBITORS MARKET SIZE, BY METASTATIC MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAF INHIBITORS MARKET SIZE, BY METASTATIC MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRAF INHIBITORS MARKET SIZE, BY METASTATIC MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DABRAFENIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DABRAFENIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DABRAFENIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ENCORAFENIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ENCORAFENIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ENCORAFENIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRAF INHIBITORS MARKET SIZE, BY VEMURAFENIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAF INHIBITORS MARKET SIZE, BY VEMURAFENIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRAF INHIBITORS MARKET SIZE, BY VEMURAFENIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRAF INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAF INHIBITORS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRAF INHIBITORS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAF INHIBITORS MARKET SIZE, BY PRIVATE HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRAF INHIBITORS MARKET SIZE, BY PRIVATE HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAF INHIBITORS MARKET SIZE, BY PRIVATE HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRAF INHIBITORS MARKET SIZE, BY PUBLIC HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAF INHIBITORS MARKET SIZE, BY PUBLIC HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRAF INHIBITORS MARKET SIZE, BY PUBLIC HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRAF INHIBITORS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAF INHIBITORS MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRAF INHIBITORS MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAF INHIBITORS MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BRAF INHIBITORS MARKET SIZE, BY GENERAL HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAF INHIBITORS MARKET SIZE, BY GENERAL HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SPECIALTY CANCER CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SPECIALTY CANCER CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SPECIALTY CANCER CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDEPENDENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDEPENDENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDEPENDENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAF INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS BRAF INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL BRAF INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 214. GCC BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. GCC BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 216. GCC BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 217. GCC BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 218. GCC BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 219. GCC BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. GCC BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 221. GCC BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. GCC BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 223. GCC BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 224. GCC BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. GCC BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 226. GCC BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 253. G7 BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 254. G7 BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 255. G7 BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 256. G7 BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 257. G7 BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 258. G7 BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. G7 BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 260. G7 BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. G7 BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 262. G7 BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 263. G7 BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. G7 BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 265. G7 BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 266. NATO BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 267. NATO BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 268. NATO BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 269. NATO BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 270. NATO BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 271. NATO BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. NATO BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 273. NATO BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 274. NATO BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 275. NATO BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 276. NATO BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. NATO BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 278. NATO BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 279. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES BRAF INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA BRAF INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)